Colorectal cancer metastatic phenotype stimulates production by fibroblasts of N-terminal peptide of type III collagen

Clinical implications for prognosis

Daniela Basso, Claudio Belluco, Saverio Mazza, Eliana Greco, Fosca Della Rocca, Paolo Pauletto, Donato Nitti, Mario Lise, Mario Plebani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In this study we assessed whether the serum levels of the N-terminal peptide of type III collagen (PIIIP), an index of type III collagen synthesis, are influenced by colorectal cancer stage, and whether "in vitro" fibroblast growth and PIIIP production could be altered by tumor tissues obtained from metastatic and nonmetastatic colorectal cancer. 208 colorectal cancer patients (115 colon and 93 rectum) were studied; 54 were stage I, 62 stage II, 37 stage III and 55 stage IV. PIIIP serum levels were significantly higher in stage IV as compared to all other patient groups. The 5-year survival of stage I, stage II, stage III and stage IV patients were 87%, 88%, 32% and 20%, respectively. In the subgroup of stage I and stage II patients considered together, PIIIP (>0.5 U/ml), but not CEA (>5 μg/l) serum levels, were predictive for survival. Fibroblast growth was significantly inhibited, while PIIIP production was significantly enhanced, when these cells were conditioned with colorectal cancer homogenates obtained from patients with distant metastases, than from those without distant metastases. In conclusion, colorectal tumors, when metastatic, stimulate fibroblasts' PIIIP synthesis and the serum levels of this peptide might predict patients' outcome after radical surgery.

Original languageEnglish
Pages (from-to)135-142
Number of pages8
JournalClinica Chimica Acta
Volume312
Issue number1-2
DOIs
Publication statusPublished - 2001

Fingerprint

Collagen Type III
Fibroblasts
Colorectal Neoplasms
Phenotype
Peptides
Tumors
Serum
Surgery
Tissue
Neoplasm Metastasis
Survival
Growth
Rectum
Colon
Neoplasms

Keywords

  • CEA
  • Colorectal cancer
  • Fibroblasts
  • Prognosis
  • Type III collagen

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Colorectal cancer metastatic phenotype stimulates production by fibroblasts of N-terminal peptide of type III collagen : Clinical implications for prognosis. / Basso, Daniela; Belluco, Claudio; Mazza, Saverio; Greco, Eliana; Della Rocca, Fosca; Pauletto, Paolo; Nitti, Donato; Lise, Mario; Plebani, Mario.

In: Clinica Chimica Acta, Vol. 312, No. 1-2, 2001, p. 135-142.

Research output: Contribution to journalArticle

Basso, Daniela ; Belluco, Claudio ; Mazza, Saverio ; Greco, Eliana ; Della Rocca, Fosca ; Pauletto, Paolo ; Nitti, Donato ; Lise, Mario ; Plebani, Mario. / Colorectal cancer metastatic phenotype stimulates production by fibroblasts of N-terminal peptide of type III collagen : Clinical implications for prognosis. In: Clinica Chimica Acta. 2001 ; Vol. 312, No. 1-2. pp. 135-142.
@article{68065e8e0967400e8f67b33f15308483,
title = "Colorectal cancer metastatic phenotype stimulates production by fibroblasts of N-terminal peptide of type III collagen: Clinical implications for prognosis",
abstract = "In this study we assessed whether the serum levels of the N-terminal peptide of type III collagen (PIIIP), an index of type III collagen synthesis, are influenced by colorectal cancer stage, and whether {"}in vitro{"} fibroblast growth and PIIIP production could be altered by tumor tissues obtained from metastatic and nonmetastatic colorectal cancer. 208 colorectal cancer patients (115 colon and 93 rectum) were studied; 54 were stage I, 62 stage II, 37 stage III and 55 stage IV. PIIIP serum levels were significantly higher in stage IV as compared to all other patient groups. The 5-year survival of stage I, stage II, stage III and stage IV patients were 87{\%}, 88{\%}, 32{\%} and 20{\%}, respectively. In the subgroup of stage I and stage II patients considered together, PIIIP (>0.5 U/ml), but not CEA (>5 μg/l) serum levels, were predictive for survival. Fibroblast growth was significantly inhibited, while PIIIP production was significantly enhanced, when these cells were conditioned with colorectal cancer homogenates obtained from patients with distant metastases, than from those without distant metastases. In conclusion, colorectal tumors, when metastatic, stimulate fibroblasts' PIIIP synthesis and the serum levels of this peptide might predict patients' outcome after radical surgery.",
keywords = "CEA, Colorectal cancer, Fibroblasts, Prognosis, Type III collagen",
author = "Daniela Basso and Claudio Belluco and Saverio Mazza and Eliana Greco and {Della Rocca}, Fosca and Paolo Pauletto and Donato Nitti and Mario Lise and Mario Plebani",
year = "2001",
doi = "10.1016/S0009-8981(01)00621-0",
language = "English",
volume = "312",
pages = "135--142",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Colorectal cancer metastatic phenotype stimulates production by fibroblasts of N-terminal peptide of type III collagen

T2 - Clinical implications for prognosis

AU - Basso, Daniela

AU - Belluco, Claudio

AU - Mazza, Saverio

AU - Greco, Eliana

AU - Della Rocca, Fosca

AU - Pauletto, Paolo

AU - Nitti, Donato

AU - Lise, Mario

AU - Plebani, Mario

PY - 2001

Y1 - 2001

N2 - In this study we assessed whether the serum levels of the N-terminal peptide of type III collagen (PIIIP), an index of type III collagen synthesis, are influenced by colorectal cancer stage, and whether "in vitro" fibroblast growth and PIIIP production could be altered by tumor tissues obtained from metastatic and nonmetastatic colorectal cancer. 208 colorectal cancer patients (115 colon and 93 rectum) were studied; 54 were stage I, 62 stage II, 37 stage III and 55 stage IV. PIIIP serum levels were significantly higher in stage IV as compared to all other patient groups. The 5-year survival of stage I, stage II, stage III and stage IV patients were 87%, 88%, 32% and 20%, respectively. In the subgroup of stage I and stage II patients considered together, PIIIP (>0.5 U/ml), but not CEA (>5 μg/l) serum levels, were predictive for survival. Fibroblast growth was significantly inhibited, while PIIIP production was significantly enhanced, when these cells were conditioned with colorectal cancer homogenates obtained from patients with distant metastases, than from those without distant metastases. In conclusion, colorectal tumors, when metastatic, stimulate fibroblasts' PIIIP synthesis and the serum levels of this peptide might predict patients' outcome after radical surgery.

AB - In this study we assessed whether the serum levels of the N-terminal peptide of type III collagen (PIIIP), an index of type III collagen synthesis, are influenced by colorectal cancer stage, and whether "in vitro" fibroblast growth and PIIIP production could be altered by tumor tissues obtained from metastatic and nonmetastatic colorectal cancer. 208 colorectal cancer patients (115 colon and 93 rectum) were studied; 54 were stage I, 62 stage II, 37 stage III and 55 stage IV. PIIIP serum levels were significantly higher in stage IV as compared to all other patient groups. The 5-year survival of stage I, stage II, stage III and stage IV patients were 87%, 88%, 32% and 20%, respectively. In the subgroup of stage I and stage II patients considered together, PIIIP (>0.5 U/ml), but not CEA (>5 μg/l) serum levels, were predictive for survival. Fibroblast growth was significantly inhibited, while PIIIP production was significantly enhanced, when these cells were conditioned with colorectal cancer homogenates obtained from patients with distant metastases, than from those without distant metastases. In conclusion, colorectal tumors, when metastatic, stimulate fibroblasts' PIIIP synthesis and the serum levels of this peptide might predict patients' outcome after radical surgery.

KW - CEA

KW - Colorectal cancer

KW - Fibroblasts

KW - Prognosis

KW - Type III collagen

UR - http://www.scopus.com/inward/record.url?scp=0034815837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034815837&partnerID=8YFLogxK

U2 - 10.1016/S0009-8981(01)00621-0

DO - 10.1016/S0009-8981(01)00621-0

M3 - Article

VL - 312

SP - 135

EP - 142

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -